Bayer Clinical Trial Pipeline — 87 Active Studies

Bayer pipeline at a glance (March 2026)

About the Bayer clinical program

Bayer's pharmaceutical pipeline is concentrated in oncology, cardiovascular disease, and an emerging radioligand therapy (RLT) platform. In oncology, Nubeqa (darolutamide) is an approved androgen receptor inhibitor for non-metastatic and metastatic castration-resistant prostate cancer, with ongoing trials in earlier-line settings. Vitrakvi (larotrectinib) and tepotinib provide kinase inhibitor coverage in TRK-fusion and MET-exon-14 cancers respectively. Bayer's radiopharmaceutical ambitions are reflected in Xofigo (radium-223) for bone-metastatic prostate cancer and a pipeline of targeted RLTs in collaboration with external partners. In cardiovascular, Kerendia (finerenone) for chronic kidney disease with type 2 diabetes, Verquvo (vericiguat) for heart failure, and next-generation Factor XIa inhibitor asundexian represent a deep late-stage CV portfolio. Xarelto (rivaroxaban) continues to generate new indication trials.

Key therapeutic areas

• Oncology (prostate, TRK-fusion, radioligand)
• Cardiovascular (Factor Xa/XIa, heart failure)
• Renal / cardiorenal (CKD, finerenone)
• Ophthalmology (VEGF-A/C/D)
• Women's health

Key pipeline programs

• Nubeqa (darolutamide) — AR inhibitor, prostate cancer
• Kerendia (finerenone) — mineralocorticoid receptor antagonist, CKD/T2D
• Xarelto (rivaroxaban) — Factor Xa, thrombosis/AF
• Vitrakvi (larotrectinib) — TRK inhibitor, TRK-fusion cancers
• Verquvo (vericiguat) — sGC stimulator, heart failure
• Asundexian — Factor XIa inhibitor, stroke prevention

Top Bayer trial indications

Condition / Indication	Trials
["Chronic Kidney Disease", "Type 2 Diabetes Mellitus"]	5
["Hemophilia A"]	4
["Chronic Heart Failure With Reduced Ejection Fraction"]	2
["Left Ventricular Systolic Dysfunction", "Heart Failure (Pediatric)"]	2
["Vasomotor Symptoms (VMS) Associated With Menopause"]	2
["Advanced Solid Tumors"]	2
["Biochemically Recurrent Prostate Cancer"]	2
["Chronic Heart Failure"]	2

Why monitor Bayer's clinical trial activity

Bayer's asundexian Factor XIa program is a closely watched anticoagulation alternative to direct oral anticoagulants — major Phase 3 readouts are expected in stroke prevention. Their Nubeqa (darolutamide) earlier-line prostate cancer trials generate competitive intelligence directly relevant to enzalutamide and apalutamide programs at competing firms.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Bayer's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Bayer trials

• Sponsor normalization: Bayer may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

What is Bayer's focus in oncology clinical trials?

Bayer's oncology pipeline spans prostate cancer (Nubeqa/darolutamide in CRPC and earlier settings, Xofigo in bone-metastatic disease), targeted oncology (Vitrakvi/larotrectinib for TRK-fusion tumors), and an emerging radioligand therapy platform. Their partnership activities in RLT are expanding the pipeline beyond radium-223.

How many Bayer trials are currently recruiting?

Based on current ClinicalTrials.gov data, 31 Bayer-sponsored trials are actively recruiting patients across oncology, cardiovascular, renal, and ophthalmology programs.

Can DataLookout track Bayer's cardiovascular trial updates?

Yes. DataLookout indexes all Bayer-sponsored ClinicalTrials.gov registrations, including cardiovascular programs for asundexian, Kerendia, Verquvo, and Xarelto. You can monitor field-level changes — status transitions, enrollment updates, and new cohort additions — alongside new trial registrations.